Abstract
Purpose :
To investigate the frequency of dry eye syndrome (DES), its clinical subtypes and risk factors among breast cancer (BC) patients undergoing endocrine therapy including selective estrogen receptor modulator (SERM) and aromatase inhibitors (AIs).
.
Methods :
This cross-sectional, observational, single visit study recruited 56 women undergoing AI treatment and 32 undergoing SERM treatment. Essential information including age, BMI, treatment situation was record. Ocular symptoms (OSDI, MGD14, IOSS) were administered. A Comprehensive Eye Surface Detector was applied to detect patients'ocular surface condition and evaluate the signs of DES. Self-Rating Anxiety Scale (SAS) and Hamilton Anxiety Scale (HAMA) were administered to evaluate patients’ anxiety and depression. Levels of blood lipid and sex hormone were examined. Chi-square analysis and logistic regression analyses were conducted to determine the frequency of DES, its clinical subtypes, and associated factors.
Results :
1. The prevalence of DES among the BC patients was 77/88 (87.50%). Among the 77 BC patients with DES, 10 patients received SERM treatment (11.36%) and 67 patients received AI treatment (76.14%). The frequencies of the clinical subtypes of dry eye were: evaporative dry eye 46/77(59.74%), aqueous deficient dry eye 18/77(23.38%), mixed dry eye 13/77(16.88%). 2.Among AI treated patients with DES, patients under 50 years had significantly heavier subjective symptoms and objective examination results of DES than those of patients older than 50 years. 3.All BC patients had different degrees of anxiety and depression, but the degree of anxiety and depression of patients with DES was significantly higher than that of patients without DES. The degree of anxiety and depression was related to the severity of DES, the heavier the degree of DES, the higher the degree of anxiety and depression. 4.Binary logistic regression analysis showed that the following factors were not significantly associated with DES: age, BMI, lipid profile, sex hormone level. Only age at receiving treatment was significantly associated with DES in BC patients.
Conclusions :
DES is possible a newly emerging side effect of endocrine therapy for breast cancer. Taking measures to intervene in the occurrence and development of DES at the initial stage of endocrine treatment for BC patients may greatly improve the patients' quality of life.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.